Published in Medical Letter on the CDC and FDA, January 14th, 2007
The LOI covers all formulations or drug combinations where phenylbutyrate is an active ingredient. Pursuant to the LOI, in addition to current worldwide rights, excluding North America, involving the current formulation of phenylbutyrate, Somanta obtains a participation in any revenue or royalties derived from its sale in North America. In return, Somanta has granted Virium a reciprocal participation in Europe. In the rest of the world, Somanta and...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.